Journal article

Relaxin family peptide receptors RXFP1 and RXFP2 modulate cAMP signaling by distinct mechanisms

Michelle L Halls, Ross AD Bathgate, Roger J Summers

Molecular Pharmacology | AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS | Published : 2006

Abstract

Two orphan leucine-rich repeat-containing G protein-coupled receptors were recently identified as targets for the relaxin family peptides relaxin and insulin-like peptide (INSL) 3. Human gene 2 relaxin is the cognate ligand for relaxin family peptide receptor (RXFP) 1, whereas INSL3 is the ligand for RXFP2. Constitutively active mutants of both receptors when expressed in human embryonic kidney (HEK) 293T cells signal through Galphas to increase cAMP. However, recent studies using cells that endogenously express the receptors revealed greater complexity: cAMP accumulation after activation of RXFP1 involves a time-dependent biphasic pathway with a delayed phase involving phosphoinositide 3-ki..

View full abstract